COMMON STOCK PURCHASE WARRANTCommon Stock Purchase Warrant • August 12th, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________[1] (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT PHARMACYTE BIOTECH, INC.Pre-Funded Common Stock Purchase Warrant • August 12th, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
UNDERWRITER COMMON STOCK PURCHASE WARRANT PharmaCyte Biotech, Inc.Underwriter Common Stock Purchase Warrant • August 12th, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
THIS Underwriter COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on August 9, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from PharmaCyte Biotech, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to the Underwriting Agreement, as defined in Section 1 herein.
PharmaCyte Biotech, Inc. 2,630,385 Shares of Common Stock (par value $0.0001 per share) 899,027 Pre-Funded Warrants to Purchase Shares of Common Stock and Warrants to Purchase 3,529,412 Shares of Common Stock Underwriting AgreementUnderwriting Agreement • August 12th, 2021 • PharmaCyte Biotech, Inc. • Biological products, (no disgnostic substances) • New York
PharmaCyte Biotech, Inc., a company incorporated under the laws of the State of Nevada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of (a) 2,630,385 shares of its common stock, par value $0.0001 per share (the “Shares”), and (b) 899,027 pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock, as such term is defined herein, at an exercise price of $0.001 per share and (ii) 3,529,412 common stock warrants to purchase 3,529,412 shares of Common Stock (the “Common Warrants”). The 2,630,385 Shares to be sold by the Company are called the “Firm Shares” and, collectively with the Pre-Funded Warrants and the Common Warrants, the “Firm Securities.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 529,411 Shares (collectively, the “Optional Shares”) and/or 529,411 Common Warrants to purchase up to an aggregate of 529,411 shares of Comm
